BioCardia
Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access
BioCardia is a biotherapeutic platform and product company based on fully developed medical device technologies.
Learn More
CORE BUSINESSES

BioCardia is engaged in two core businesses:

Helix Biotherapeutic Delivery offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart.

Morph Access Innovations develops advanced catheter products for interventional medicine.

HELIX NEWS

March 10, 2009
TABMMI Heart Failure Stem Cell Clinical Trial Results Presented; Improvements Sustained at Three Year Follow-up

March 5, 2009
TAC-HFT Stem Cell Trial Completes Early Safety Phase

more newsmore publications

MORPH NEWS

May 2009
Morph® AccessPro™ Receives FDA Clearance

March 2009
A new article has been published in the March 2009 issue of Endovascular Today entitled “Celiac Artery Stenting.”


more news
more publications